Business News • PR NewsWire • Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with the hepatitis C virus (HCV) and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated...

View More : http://www.prnewswire.com/news-releases/final-data-from-the-phase-2-cosmos-study-of-janssens-once-daily-simeprevir-in-co...

Releted News by prnewswire

La vitamina D relacionada con la enfermedad del hígado graso en niños de Reino Unido

SDN Market 2014-2019 & NFV Industry 2014-2020 Research Reports

China Circulating Fluidised Bed (CFB) Boiler Industry 2018 Analysis Based on Capacity

Housing Market Trends For 2014 - Loan Love Predicts Changes For Borrowers